University Hospital Tuebingen clinical trial pipeline

5 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 2 with minor changes only.

1. Notable

   Blood and Tissue Extraction for Immunological Examinations During…Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas

   Primary completion pushed from Jul 21, 2026 to Dec 31, 2028

   Also in this update: Enrollment closed, study ongoing; Study completion moved earlier from Jul 21, 2031 to Dec 31, 2028

   University Hospital Tuebingen·Not applicable· NCT06385288· Registry history of NCT06385288 on ClinicalTrials.gov (opens the registry)

   Updated Oct 13, 2026

2. Notable

   PRIDE · Protective VEGF Inhibition for Isotoxic Dose Escalation…PRIDE · Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma

   Primary completion pushed from Apr 10, 2028 to Dec 31, 2028

   Also in this update: Enrollment closed, study ongoing; Final enrollment: 107 participants (planned 146)

   University Hospital Tuebingen·Phase 2· NCT05871021· Registry history of NCT05871021 on ClinicalTrials.gov (opens the registry)

   Updated Sep 29, 2026

3. Notable

   CINPLASTA · Low-thermal Argon Plasma Devitalization · CIN 2…CINPLASTA · Low-thermal Argon Plasma Devitalization · CIN 2 Versus Standard of Active Surveillance

   Recruitment opened

   University Hospital Tuebingen·Not applicable· NCT07730645· Registry history of NCT07730645 on ClinicalTrials.gov (opens the registry)

   Updated Oct 1, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.